NanoViricides Begins Trading on NYSE MKT National Exchange; CEO Dr Seymour Invited to Speak at Duke University’s Fuqua

  NanoViricides Begins Trading on NYSE MKT National Exchange; CEO Dr Seymour
  Invited to Speak at Duke University’s Fuqua Business School

Business Wire

WEST HAVEN, Conn. -- September 25, 2013

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that its
stock began trading today on the NYSE MKT National Exchange under its original
symbol, NNVC.

In another Company news, our CEO, Eugene Seymour, MD, MPH, is invited to speak
at the Duke University Fuqua School of Business today afternoon. His talk will
focus on policies that can help accelerate the development of pharmaceuticals
against diseases that pharma companies would otherwise not have much interest
in, or “orphan drug” development.

Dr. Seymour will discuss the economic incentives associated with orphan drug
development, focusing on the importance of the Priority Review Voucher (PRV),
and their relevance to the decision-making process of both small and large
pharmaceutical and biotech companies. He will illustrate his arguments using
the example of DengueCide™, the Company’s nanoviricide drug against dengue,
that has been designated an “orphan drug” by the US FDA.

As noted in Monday’s press release, Scott Cutler, Executive Vice President,
Head of Global listing, NYSE Eurotext, made the following statement about the
Company and the new listing: “We congratulate NanoViricides on their listing
with NYSE MKT. Our community ranges across a variety of industries and it is
always exciting for a biotech company like NanoViricides to benefit from our
platform and further support their research and development.”

The concept of the PRV was initially developed by three professors, David
Ridley, Jeff Moe and Henry Grabowski at the Fuqua School of Business of the
Duke University. Dr. Ridley invited Dr. Seymour to speak on the importance of
economic incentives to help innovative pharmaceutical companies attach higher
priorities to drug development programs against “orphan” diseases.

The Priority Review Voucher concept that the professors developed was embraced
by the US FDA. Currently, the US FDA’s list of diseases for which no adequate
therapy exists that are eligible for a PRV contains about 16 diseases. Dengue
is at present the only viral disease on the list. The existence of the PRV was
an important factor in the Company’s decision to assign a high priority to its
dengue drug development program.

NYSE MKT is considered a premier US equities market for listing and trading of
small growth companies. NYSE MKT is a fully integrated trading venue within
the NYSE Euronext community and leverages the NYSE's advanced and innovative
market model to offer a premier venue for listing and trading the stocks of
small companies. The venue utilizes the trading, connectivity and routing
technologies of the NYSE platform and offers superior price discovery,
superior liquidity and reduced trading volatility. Listed companies benefit
from issuer-selected Designated Market Makers (DMM) that utilize world-class
NYSE trading systems to discover and improve prices, dampen volatility, add
liquidity and enhance value. In addition, NYSE MKT-listed companies gain
access to the brand visibility and are eligible for the issuer services
enjoyed by the NYSE Euronext community.

NanoViricides, Inc. currently has six drug development pipeline indications
and several research programs. The Company is advancing both an injectable
drug and an oral drug against Influenzas in IND-enabling studies in its
FluCide™ program. The oral FluCide drug is being developed for out-patient
influenza cases. The injectable FluCide is being developed for the seriously
ill, hospitalized patients with influenza-like illness. Both of these drugs
are broad-spectrum, i.e. they are expected to work against most if not all
influenza A viruses. The Company believes so because the virus-binding ligand
in these drugs mimics the component of the cell receptor known to be used by
all influenza viruses in order to gain entry into the cell. Both of these
anti-influenza drugs may also be useful for prophylaxis, such as for the
protection of health care workers. In addition, the Company has developed
several other highly effective nanoviricides. These include HIVCide™,
HerpiCide™, DengueCide™, and a broad-spectrum nanoviricide eye drop
formulation for the treatment of epidemic keratoconjunctivitis (EKC), a viral
infection of the eye. The Company’s drug programs are based on the Company’s
patented “nanoviricide®” platform technology that enables specifically
targeting a particular type of virus with a novel mechanism of action. In
addition, the Company’s other research and development programs include (a)
broad-spectrum nanoviricides against a number of Neglected Tropical Diseases,
and (b) its novel ADIF™ ( “Accurate Drug In Field”™ ) technologies which
promise a way to attack novel viruses, whether man-made (bioterrorism) or
natural (such as SARS), before they can cause a pandemic.

About NanoViricides:

NanoViricides, Inc. ( is a development stage company
that is creating special purpose nanomaterials for antiviral therapy. The
Company's novel nanoviricide® class drug candidates are designed to
specifically attack enveloped virus particles and to dismantle them. The
Company is developing broad-spectrum drugs against a number of viral diseases.
The Company’s development candidates include an anti-influenza injectable drug
and an anti-influenza oral drug; both expected to be effective against most
types of influenza viruses including H1N1 swine flu, H5N1 bird flu, seasonal
Influenzas, and possibly the recent threat of novel H7N9 influenza A virus. In
addition, the Company is also developing drugs against HIV, oral and genital
Herpes, viral diseases of the eye including EKC and herpes keratitis, and
Dengue viruses. The Company’s research programs include Hepatitis C, Rabies,
and Ebola virus, among others.

This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events could
differ materially and substantially from those projected herein and depend on
a number of factors. Certain statements in this release, and other written or
oral statements made by NanoViricides, Inc. are “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. You should not place undue
reliance on forward-looking statements since they involve known and unknown
risks, uncertainties and other factors that are, in some cases, beyond the
Company's control and which could, and likely will, materially affect actual
results, levels of activity, performance or achievements. The Company assumes
no obligation to publicly update or revise these forward-looking statements
for any reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking statements, even if
new information becomes available in the future. Important factors that could
cause actual results to differ materially from the Company's expectations
include, but are not limited to, those factors that are disclosed under the
heading "Risk Factors" and elsewhere in documents filed by the company from
time to time with the United States Securities and Exchange Commission and
other regulatory authorities. Although it is not possible to predict or
identify all such factors, they may include the following: demonstration and
proof of principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our product
candidates; and market acceptance of our products.


NanoViricides, Inc.
Amanda Schuon, 310-550-7200
Press spacebar to pause and continue. Press esc to stop.